For reprint rights or to purchase a copy of your Daily Journal photo, email jeremy@reprintpros.com for prices or call 949-702-5390.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Menu
  • Sign In

    • Pearl O'Neill v. Novartis Consumer Health Inc.

    Sep. 8, 2004
    Verdicts and settlements
    Sign up for Daily Journal emails
    Personal Injury
    Product Liability
    Pharmaceutical

    Pearl O'Neill v. Novartis Consumer Health Inc.

    Published: Sep. 8, 2004 | Result Date: Feb. 6, 2004 | Filing Date: Jan. 1, 1900 |
    Case number: 01CC070503 Verdict –  $0

    Judge

    Anthony J. Mohr

    Court

    L.A. Superior Central West


    Attorneys

    Plaintiff

    Ramon Rossi Lopez
    (Lopez McHugh LLP)

    Mark P. Robinson Jr.
    (Robinson Calcagnie Inc.)


    Defendant

    Jan E. Dodd
    (Shook Hardy & Bacon LLP)

    Aton Arbisser


    Experts

    Plaintiff

    Raymond Lake
    (medical)

    Jerome Avorn
    (medical)

    Hugh McIntyre
    (medical)

    Henry Pribham
    (medical)

    Mark Fisher
    (medical)

    James C. Parker
    (Hugo Parker LLP) (technical)

    Douglas E. Harrington
    (medical)

    Susan Hurst
    (medical)

    Defendant

    Donald Goldman
    (medical)

    Gerald Faich
    (technical)

    Mark Alberts
    (medical)

    Paul Bowie Watkins Jr.
    (medical)

    Facts

    In April 1995, plaintiff Pearl O'Neill, 35, took a single dose of Tavist-D for a sinus headache. The medicine contained phenylpropanolamine (PPA). After taking the medicine, the plaintiff suffered an intracerebral hemorrhage. Five years later, the Food and Drug Administration requested that all drug manufacturers remove PPA from their over-the-counter products. A study had shown that PPA increases the risk of stroke.

    Injuries

    The plaintiff's hemorrhage led to psychological and cognitive difficulties that made her unable to continue her work as a legal secretary.

    Deliberation

    2.5 days

    Poll

    9-3 (design defect), 10-2 (failure to warn), 10-2 (fraud by concealment)

    Length

    3.5 months


    #98047

    For reprint rights or to order a copy of your photo:

    Email jeremy@reprintpros.com for prices.
    Direct dial: 949-702-5390

    By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.